Brief: Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
08/07/2024 13:56
July 8 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O :
* MIRUM PHARMACEUTICALS’ LIVMARLI APPROVED IN THE EUROPEAN
UNION
FOR PATIENTS WITH PFIC
* MIRUM PHARMACEUTICALS : LIVMARLI ALSO RECEIVED POSITIVE
COMP
OPINION RECOMMENDING MAINTENANCE OF ORPHAN DRUG DESIGNATION IN
PFIC
* MIRUM PHARMACEUTICALS : EUROPEAN COMMISSION GRANTS
LIVMARLI
MARKETING AUTHORIZATION FOR TREATMENT OF PFIC IN PATIENTS THREE
MONTHS & OLDER
Source text for Eikon: ID:nBw7h9qYla
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX